Product Name |
Acalabrutinib
|
Product Code |
A0000190
|
Chemical name |
Acalabrutinib
|
Synonyms |
4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; ACP 196
|
Impurity |
|
CAS Number |
1420477-60-6
|
Alternate CAS # |
NA
|
Molecular form |
C₂₆H₂₃N₇O₂
|
Appearance |
|
Melting Point |
|
Mol. Weight |
465.51
|
Storage |
|
Solubility |
|
Stability |
|
Category |
|
Boiling Point |
|
Applications |
Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton’s tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).
|
Dangerous Goods Info |
NA
|
References |
Byrd; et al. (2015). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia."; "AstraZeneca to buy Acerta for blood cancer drug". www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015.
|
Extra Notes |
|
Documents (MSDS) |
No Data Available
|
Keywords |
Buy 1420477-60-6 | Purchase 1420477-60-6 | Order 1420477-60-6 | 1420477-60-6 supplier | 1420477-60-6 manufacturer | 1420477-60-6 distributor | 1420477-60-6 cost |